MOLBIODIAGNOSTICS Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹408 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹10.4 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Molbio Diagnostics reported Q1 FY27 revenue of ₹48 crore with EBITDA of ₹10.4 crore (25% margin) and PAT of ₹5.27 crore. The company, fresh from its IPO, is a point-of-care molecular diagnostics play with the proprietary TruNAT platform (12,500+ machines globally, 30+ tests). The TB business dominates domestic revenues (~90%), with a newly renewed 2-year government contract. Key concerns include: device sales appearing to decline YoY (historically 2200-2600 annually), Optra Scan (digital pathology subsidiary) remaining loss-making through FY27 post-July FDA clearance, and limited visibility on HPV government program volumes. Management guided to ~25% revenue growth and 24-25% EBITDA for FY27 but acknowledged non-linear quarterly patterns. Test kit volumes (62.4 lakh kits, 164 devices in Q1) showed mixed trends versus Q4. The bull case hinges on geographic expansion (Europe IVDR, US market entry), new disease tests (22 in pipeline), and non-communicable disease platform development (10x the infectious disease opportunity). Key risk: heavy TB program concentration with government funding cycles and potential pricing pressure from product mix shifts.
Colored figures show movement against the previous available record.
Guidance to track
- Management guided to approximately 25% topline growth for FY27 based on current order visibility and expansion plans.
- Full-year EBITDA margin guidance of 24-25% implies margin stability with potential for improvement as consumable mix increases.
- Company renewed its 2-year TB supply contract with Government of India just last month, providing near-term revenue visibility.
- Management expects to provide specific volume guidance for HPV government program in the next quarterly call as program details crystallize.
- Digital pathology subsidiary (60% owned, fresh $30M capital) received US FDA clearance in July 2025; expected to turn profitable from FY28 onwards.
Risks flagged
- Historical device sales range 2200-2600 annually; Q1 FY27 at 164 devices appears seasonally weak but raises questions about whether the addressable market is saturating in core TB programs. Management deflected on explaining the volume realization decline.
- Management acknowledged they cannot provide specific volume guidance for the HPV national program at this stage, deferring to next quarter. This represents unquantified revenue upside at a company trading at IPO valuations.
- Digital pathology subsidiary expected to remain loss-making through FY27, creating a ~9 crore annual drag at the PAT level while consuming management bandwidth during critical US market entry.
- ~90% of domestic revenue tied to government TB program creates dependency on funding allocations, tender pricing, and political prioritization. Any policy shift or budget constraint could materially impact results.
- Export revenue at ~16% of total is volatile (described as 'up and down') and management acknowledged 3-year ramp-up timeline with registrations ongoing across 90+ countries. No clear acceleration path articulated.
Key quotes
- The business is not linear... We would urge you to track us on an annual basis.
- Optra Scan this year will be muted. We don't expect the company to turn profitable in FY27 but going forward 28 and 29 onwards we should see meaningful contribution coming in.
- Currently about 77% of revenue contributed from test kits. The recurring revenue business has kicked in as per our plans.
- We are just about getting started in the international landscape so while obviously other diseases will kick in, TB itself has a lot more for us to do.
Research modules